Opinion|Videos|February 28, 2025
Patient-Centered Selection of BTK Inhibitors: Balancing Clinical Factors and Patient Preferences
Panelists discuss how clinical and patient-specific factors, such as comorbidities, age, and risk profiles, influence the selection of Bruton tyrosine kinase (BTK) inhibitors for treatment-naive patients with chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) while also considering how these factors align or differ from patient preferences regarding treatment duration, adverse effect profiles, and lifestyle impact.
Advertisement
Episodes in this series
- What clinical and patient-specific factors influence your treatment selection between BTK inhibitors for treatment-naive patients with CLL and MCL?
- How do your factors align with or differ from your patients’ preferences and values?
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
ATTR-CM Incidence, Prevalence Rose Sharply in the US
2
CDC Officially Ends Hantavirus Response as Outbreak Risk Recedes
3
First Generic of Priftin Approved by FDA for Tuberculosis Treatment and Prevention
4
Mixed Phase 3 Results for IB6-Targeting ADC Raise Questions on Optimal Use in NSCLC
5